Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection

By sjmartinez • June 13, 2025

Guo Q, Parikh K, Zhang J, Brinkley A, Chen G, Jakramonpreeya N, Zhen A, An DS. Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection. Mol Ther Methods Clin Dev. 2025 May 15;33(2):101486. doi: 10.1016/j.omtm.2025.101486. PMID: 40503012; PMCID: PMC12152878.

Tags: C46 membrane-anchored HIV-1 fusion inhibitor, CCR5 short hairpin RNA, CD4-based anti-HIV-1 chimeric antigen receptor, cetuximab-mediated in vivo negative selection, Hematology/Oncology, hematopoietic stem/progenitor cell-based gene therapy, HIV-1, HSPC, huEGFRt, humanized mouse, Publications, truncated human EGFR

Related Posts

Promising New Platforms and Targets in the Management of Gastroesophageal Cancers

Yoon J, Chen CY, Watson R, Smyth E, Wainberg Z, Oh DY. Promising New Platforms and Targets in the Management of Gastroesophageal Cancers. Am Soc[...]

Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates

Davenport S, Xie B, Hamblett K, Hausman D, Villalobos I, Singh HP, Cobrinik D, Hoon DSB, Zhou JY, Sibug-Saber M, Ma Y, Konecny GE, Heur[...]

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer

Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, Punekar SR, Barve M, Pelster M, Herzberg B, Azad NS, Hecht JR, Ou[...]